AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3527720
Drug: Bay m
RxNorm normalized name: ZINC OXIDE 94 mg in 1 mL TOPICAL LOTION [Cay Skin MoBay Mineral Sunscreen Drops SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay m 1099 (100 mg before breakfast and dinner)
Trial: 29763657
Drug: mHealth-based care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth-based care model (daily BP measurement using smartphone and wireless BP monitor, bi-weekly medication adjustments)
Trial: 20070849
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) intervention for panic symptoms
Trial: 16372827
Drug: Onercept 5mg
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 5mg and 50mg (single intravenous doses)
Trial: 16372827
Drug: Onercept 15mg
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 15mg and 150mg (single intravenous doses)
Trial: 16372827
Drug: Onercept 50mg
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 50mg (single intravenous, subcutaneous and intramuscular doses)
Trial: 16372827
Drug: Onercept 50mg
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 50mg (repeat subcutaneous administration of six doses every 48 hours)
Trial: 16372827
Drug: Onercept 100mg
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 100mg and 150mg (repeat subcutaneous administration of six doses over 2 weeks)
Trial: 11235499
Drug: New nonprescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New nonprescription medication
Trial: 9703836
Drug: 5-FU 250
RxNorm normalized name: 5-FU 250 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 250 mg/day with Limethason 1 A (4.0 mg of dexamethasone palmitate) in Group B
Trial: 9703836
Drug: 5-FU 250
RxNorm normalized name: 5-FU 250 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 250 mg/day in Group A
Trial: 7816530
Drug: Diuretics treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics treatment in infants with congenital heart disease
Trial: 3050936
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg single dose
Trial: 3050936
Drug: Ketanserin 20
RxNorm normalized name: ketanserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20 mg b.d. chronic dosing
Trial: 3050936
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg b.d. chronic dosing
Trial: 3050936
Drug: Ketanserin mean
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin mean dose 73 mg/day for 7 weeks
Trial: 3050936
Drug: Ketanserin mean
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin mean dose 167 mg/day
Trial: 25879460
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg OaD
Trial: 25879460
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg PRN
Trial: 19223620
Drug: IPTi-SP (sulfadoxine-pyrimethamine)
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPTi-SP (sulfadoxine-pyrimethamine) administered at 3, 9, and 15 months of age
Trial: 15031611
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (E20, L10, P)
Trial: 11180494
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy combined with placebo
Trial: 11180494
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy combined with melatonin
Trial: 9663225
Drug: Adjunctive subconjunctival
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive subconjunctival mitomycin C (MMC) during primary glaucoma triple procedure
Trial: 9663225
Drug: Adjunctive subconjunctival
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive subconjunctival mitomycin C (MMC) for 3 minutes
Trial: 9663225
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no adjunctive mitomycin C)
Trial: 7829176
Drug: 0.03% flurbiprofen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% flurbiprofen, administered 6 times at 15 minute intervals 90 minutes preoperatively in addition to the routine dilation regimen.
Trial: 7829176
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no flurbiprofen treatment).
Trial: 3278412
Drug: CDP-choline (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-choline (1,000 mg/day i.v. once daily for 14 days)
Trial: 31230026
Drug: 6-month supervised
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month supervised training courses (weekly gym training and Taiji sessions), followed by a free 6-month unsupervised use of exercise facilities, and unsupervised low-cost exercise for another 12 months
Trial: 29151036
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy (losartan 50-100 mg plus hydrochlorothiazide 12.5-25 mg)
Trial: 29151036
Drug: Initial monotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial monotherapy (losartan 50-100 mg or hydrochlorothiazide 12.5-25 mg)
Trial: 29151036
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (losartan 100 mg and hydrochlorothiazide 12.5 to 25 mg) in phase 2
Trial: 21604900
Drug: 40-session cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-session cognitive treatment
Trial: 9713471
Drug: CDDP‐MS containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP‐MS containing 200 mg of cisplatin (n = 5)
Trial: 9713471
Drug: CDDP‐S containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP‐S containing 100 mg of cisplatin (n = 10)
Trial: 8148215
Drug: Oxcarbazepine (OXC)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OXC) 600 mg single dose followed by 300 mg thrice daily for 3 weeks
Trial: 8148215
Drug: Oxcarbazepine (OXC)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OXC) 300 mg thrice daily for 3 weeks
Trial: 8148215
Drug: Oxcarbazepine (OXC)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OXC) as add-on therapy
Trial: 2454440
Drug: Opioids (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids (morphine or equivalent doses)
Trial: 30529378
Drug: Crestal implants
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crestal implants (placed approximately 2 mm below the bone crest)
Trial: 30529378
Drug: Subcrestal implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcrestal implants (placed at bone crest level)
Trial: 22925498
Drug: Hyaluronic acid-9
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid-9 group (4 weekly instillations of 40 mg followed by 5 monthly instillations)
Trial: 22925498
Drug: Hyaluronic acid-12
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid-12 group (12 instillations of 40 mg every 2 weeks)
Trial: 16506061
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 mg)
Trial: 15585783
Drug: Short-chain fructooligosaccharides
RxNorm normalized name: fructooligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-chain fructooligosaccharides (10 g/d)
Trial: 15585783
Drug: Soybean oligosaccharides
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oligosaccharides (10 g/d)
Trial: 15585783
Drug: Galactooligosaccharides (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galactooligosaccharides (10 g/d)
Trial: 15585783
Drug: Type III
RxNorm normalized name: Collagen type III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type III resistant starch (10 g/d)
Trial: 15585783
Drug: NDCHs (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDCHs (2.5, 5.0, 7.5, or 10 g/d)
Trial: 11760223
Drug: Nelfinavir suspension
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nelfinavir suspension (1250 mg in 100 mL of water)
Trial: 11760223
Drug: Nelfinavir tablets
RxNorm normalized name: Nelfinavir Tablets
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nelfinavir tablets (five 250-mg tablets)
Trial: 11760223
Drug: Nelfinavir suspension
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nelfinavir suspension
Trial: 3811814
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (30 mg i.v. bolus followed by 1 mg/min for 8 hours)
Trial: 26846333
Drug: Roxadustat (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (1.5 to 2.0 mg/kg)
Trial: 26846333
Drug: Roxadustat (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (2.0 mg/kg)
Trial: 17963858
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal ring (RING) releasing 15 mcg ethinyl estradiol and 120 mcg etonogestrel per day
Trial: 17963858
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive (PILL) containing 20 mcg ethinyl estradiol and 100 mcg levonorgestrel daily
Trial: 10365352
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly supervised oral iron administration (group B)
Trial: 10365352
Drug: Daily unsupervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily unsupervised oral iron administration (group A)
Trial: 10365352
Drug: Parenteral iron
RxNorm normalized name: Iron, parenteral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral iron (group C)
Trial: 26773735
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for standard-risk ALL
Trial: 25547786
Drug: Levofloxacin-based triple
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-based triple therapy (LAL): levofloxacin 500 mg daily, amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Trial: 25547786
Drug: Moxifloxacin-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin-based triple therapy (MAL): moxifloxacin 400 mg daily, amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d. for 10 days
Trial: 25547786
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (CAL): clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d., lansoprazole 30 mg b.i.d.
Trial: 1680982
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (hydralazine + sorbitrate)
Trial: 17542352
Drug: Generic oral
RxNorm normalized name: Generlac Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic oral solution of risperidone (1 mg)
Trial: 17542352
Drug: Risperdal tablets
RxNorm normalized name: Risperdal
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperdal tablets (1 mg)
Trial: 15356547
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment for asthma
Trial: 12297482
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition supplemented with 20 g/d L-arginine for 7 days
Trial: 9708936
Drug: Chemotherapy supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy supported with G‐CSF (5 microg/kg subcutaneously on Days 2‐13; Arm B)
Trial: 9708936
Drug: Chemotherapy supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy supported with G‐CSF (Arm B)
Trial: 19481229
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (118 mL daily for 6 months)
Trial: 19481229
Drug: White wine
RxNorm normalized name: White wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wine (118 mL daily for 6 months)
Trial: 7974677
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg chlorproguanil daily
Trial: 7974677
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg proguanil daily
Trial: 7974677
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg chlorproguanil weekly
Trial: 7974677
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg calcium lactate weekly (placebo)
Trial: 409052
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate 10 mg, four times a day
Trial: 31860534
Drug: L-Citrulline (CIT)
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-Citrulline (CIT) 6 g·d for 7 days
Trial: 31860534
Drug: L-Citrulline (CIT)
DrugBank: Citrulline (DB00155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-Citrulline (CIT)
Trial: 30971596
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion at 15 mg/kg/h
Trial: 11360129
Drug: Beta-carotene (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (42 mg)
Trial: 9245870
Drug: Teicoplanin administered
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin administered to half the patients at the start of the procedure
Trial: 30354397
Drug: Omega-3 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 therapy (4 mg/d for 310±87 days)
Trial: 30354397
Drug: Omega-3 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 therapy
Trial: 27184297
Drug: Control Therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Therapy
Trial: 24968280
Drug: Liquid protein
RxNorm normalized name: ProMod Liquid Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid protein snack containing 30 g carbohydrates and 30 g proteins (casein, whey protein or an equal mix of the two; n 26-28 per group)
Trial: 24968280
Drug: Control snack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control snack containing 60 g maltodextrin
Trial: 12814458
Drug: Gliclazide 80
RxNorm normalized name: gliclazide 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide 80 mg BID for 4 weeks
Trial: 12814458
Drug: Glimepiride 2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 2 mg OD for 4 weeks
Trial: 8859194
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose leucovorin (20 mg/m2/day by intravenous bolus) and 5-fluorouracil (425-600 mg/m2/day for 5 consecutive days every 28 days)
Trial: 8859194
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose leucovorin and 5-fluorouracil
Trial: 24594851
Drug: Lake Hévíz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lake Hévíz thermal mineral water therapy (n = 38)
Trial: 24594851
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (tap water therapy, n = 39)
Trial: 22248752
Drug: Vasoactive drugs
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive drugs (dopamine + norepinephrine)
Trial: 22248752
Drug: Vasoactive drugs
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive drugs (dopamine + norepinephrine + IABP therapy)
Trial: 12038884
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg per day of enteral iron
Trial: 12038884
Drug: 12 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/kg per day of enteral iron
Trial: 31551606
Drug: IV1 (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV1 (loading dose 15 mg TXA/kg single intravenous administration)
Trial: 31551606
Drug: IV2 (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV2 (loading dose 15 mg TXA/kg + additional dose 15 mg TXA/kg 6 h after the first application)
Trial: 31551606
Drug: COMB (IV1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMB (IV1 + local wash of 2 g of TXA in 50 mL of saline)
Trial: 31551606
Drug: TOP (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOP (topical administration of 2 g of TXA in 50 mL of saline)
Trial: 28719281
Drug: Handwashing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handwashing with soap and water treatment intervention
Trial: 23516412
Drug: Olive leaf
RxNorm normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive leaf extract (OLE) 51.1 mg oleuropein, 9.7 mg hydroxytyrosol per day
Trial: 19233390
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor electrical stimulation plus biofeedback (twice a week for 6 weeks, starting 7 days after catheter removal)
Trial: 2449013
Drug: Topical clobetasol-17-propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol-17-propionate (CP)
Trial: 29924393
Drug: Oral nutrition
RxNorm normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutrition alone (n = 124 days, 55%)
Trial: 29924393
Drug: Oral nutrition
RxNorm normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutrition in combination with enteral nutrition (n = 96 days, 42%)
Trial: 26388465
Drug: Low-concentration protocol
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-concentration protocol (240 mg I/mL, 80 kVp)
Trial: 26388465
Drug: Conventional protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional protocol (350 mg I/mL, 120 kVp)
Trial: 12900684
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of pseudoephedrine hydrochloride (D)
Trial: 9354192
Drug: mesalazine 500
RxNorm normalized name: mesalazine 500 Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalazine 500 mg t.d.s.
Trial: 9354192
Drug: oral preparation
RxNorm normalized name: Iron bivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral preparation of viable E. coli strain Nissle (Serotype 06: K5: H1)
Trial: 24639432
Drug: Lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 20 µg once daily
Trial: 18675402
Drug: Enhanced group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced group (weekly moderated online chat sessions)
Trial: 12450905
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL CGJ.kg(‐1).d(‐1)
Trial: 7193004
Drug: Oral enzyme
RxNorm normalized name: alpha-D-galactosidase enzyme Disintegrating Oral Tablet [Beano]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enzyme preparation of trypsin/chymotrypsin (Chymoral 100/F)
Trial: 25380743
Drug: Single-port laparoscopic
RxNorm normalized name: ADAPTER,ENFIT,20FR,SINGLE PORT,G-TUBE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-port laparoscopic rectal surgery
Trial: 25380743
Drug: Conventional laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional laparoscopic rectal surgery
Trial: 19714856
Drug: LGG and
RxNorm normalized name: Enfamil Nutramigen Toddler with Enflora LGG and Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGG and L. gasseri TMC0356 fermented milk